Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NatHaLi-01 UCART20x22 in relapsed or refractory B-cell non-Hodgkin lymphoma
2022-501607-27-00Phase 2Authorised
- Sponsor
- Cellectis
- Start
- Apr 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 4
01
Overview
Phase 2, open-label trial of UCART20x22 in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 3 more (2 arms), sponsored by Cellectis. Primary endpoints: Safety in dose-finding part, Dose-limiting toxicity rate and 2 more. Planned start Apr 2023; status: authorised.
02
Drugs
UCART20x22
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2022-501607-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501607-27-00.